Renovacor Reports First Quarter 2022 Financial Results and Provides Corporate Update
REN-001 advancing toward IND submission in the second half of 2022 with the initiation of a Phase I/II clinical trial in BAG3-DCM expected thereafter
Strengthened executive team with appointment of Fred Driscoll as CFO